Please assess the completion status of the following clinical trial:

Trial Title: Phase III Study of BMS-188667 (CTLA4Ig) in Patients With Rheumatoid Arthritis Who Are Currently Failing Anti-TNF Therapy or Who Have Failed Anti-TNF Therapy in the Past.

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Eligibility Criteria:~* Active rheumatoid arthritis currently failing anti-TNF therapy or have failed anti-TNF therapy in the past.~Exclusion Criteria:~* Women who are pregnant or breast feeding~* Current symptoms of serious medical disease~* History of cancer in last 5 years other than non-melanoma skin cancer~* Chronic serious infection~* Active TB requiring treatment in last 5 years~* Herpes zoster in last 2 months~* Any active viral infection including Human Immunodeficiency Virus (HIV)~* Serious side effects associated with previous anti-TNF therapy

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Abatacept (Type: ACTIVE_COMPARATOR): Short Term Portion of Study
- Placebo (Type: PLACEBO_COMPARATOR): Short Term Portion of Study
- Abatacept (Long Term) (Type: ACTIVE_COMPARATOR): Long Term Portion of Study:~All participants receive Active Drug

Based on this trial design, predict the completion outcome and termination type (if applicable).